StockData
uniQure N.V. logo

uniQure N.V. (QURE) company profile

QURENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30224% above fair value
$20.30−0.48 (-2.31%)

Close on Nov 18, 2026Market cap $1.41BP/E –Yield –

About uniQure

Pharmaceutical Preparations, SIC 2834

uniQure is a biotechnology company that develops genomic medicines and adeno-associated virus-based gene therapies for individuals living with severe genetic and debilitating illnesses. Its pipeline of investigational clinical treatments targets central nervous system and metabolic disorders, including Huntington’s disease, refractory mesial temporal lobe epilepsy, Fabry disease, and amyotrophic lateral sclerosis. The company also developed etranacogene dezaparvovec for hemophilia B, which is commercialized globally by partner CSL Behring under the brand name HEMGENIX.

The company operates internationally, conducting clinical trials across the United States and Europe, and previously maintained manufacturing operations in Lexington, Massachusetts. It maintains corporate subsidiaries, including uniQure France SAS, and manages an intellectual property portfolio spanning jurisdictions such as the United States, Europe, Australia, Japan, and Canada. The provided report does not state the company's headquarters location.

Summary of the business section of uniQure's latest annual report, written by StockData.

Company profile

Company

Legal name
uniQure N.V.
Headquarters
Amsterdam, Netherlands
Address
Paasheuvelweg 25a 1105 BP
Phone
1-339-970-7000
Employees
221, Dec 31, 2025
Industry
Pharmaceutical Preparations
Fiscal year ends
December 31
Auditor
KPMG Accountants N.V., Amstelveen, the Netherlands

Stock & identifiers

Ticker
QURE
Exchange
Nasdaq
IPO date
Feb 6, 2014
Shares outstanding
69M, Jul 24, 2026
Public float
$764.80M, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1590560
CUSIP
N90064101
FIGI
BBG005SSJYH3
Share class FIGI
BBG005SSJYG4
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Matthew C. KapustaCEO, Managing Director531,109
Walid Abi-SaabChief Medical Officer166,985
Jeannette PottsChief Legal Officer133,246
Kylie O'KeefeChief Customer & Strat Officer108,864
Christian KlemtChief Financial Officer238,581
David D. MeekDirector30,667
Jack KayeDirector43,056
Madhavan BalachandranDirector49,644
Leonard E. PostDirector35,494
Robert GutDirector32,259
Jeremy P. SpringhornDirector43,251
Rachelle Suzanne JacquesDirector33,903

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$3.29M$7.17M$1.90M$66$120
FY2024$3.08M$9.94M$1.52M$48$90
FY2023$6.58M-$1.40M$2.67M$19$92
FY2022$5.63M$6.96M$2.35M$63$89
FY2021$5.10M$1.56M$2.34M$57$99
FY2020$4.47M-$7.34M$2.28M$50$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Matthew Kapusta
Chief Executive Officer
$676.17K$1.08M$1.16M$345.12K$31.09K$3.29M+7%
Christian Klemt
Chief Financial Officer
$539.22K$795.70K$851.76K$197.76K$22.98K$2.41M+81%
Walid Abi-Saab
Chief Medical Officer
$583.80K$414.20K$446.16K$258.25K$103.23K$1.81M+20%
Jeannette Potts
Chief Legal and Compliance Officer
$495.01K$381.50K$405.60K$178.34K$39.47K$1.50M+16%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Feb 6, 2014
Offer price
$17.00
Securities offered
5,400,000
Gross proceeds
$91.80M
Exchange
Nasdaq
First trading day
Feb 5, 2014
First-day close
$14.61-14.1%
Lock-up ends (est.)
Aug 4, 2014

“PER ORDINARY SHARE TOTAL Public Offering Price $ 17.00 $ 91,800,000 Underwriting Discounts and Commissions (1) 1.19 6,426,000 Proceeds to uniQure before Expenses 15.81 85,374,000 (1) The underwriters will also be reimbursed for certain expenses incurred in this offering.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had a total of 221 employees, 126 of whom are based in The Netherlands, 83 in the U.S.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jul 23, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 29, 2019Auditor changeChange in certifying accountant (8-K Item 4.01)
Feb 6, 2014IPOInitial public offering priced (424B4 prospectus)
Feb 6, 2014Name changeName changed from uniQure B.V. to uniQure N.V.
Jan 31, 2014ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?